"Discourse with Aroon Hingorani: The Prevention Paradox Unveiled"

"Discourse with Aroon Hingorani: The Prevention Paradox Unveiled"

In the realm of medical research, age remains a significant predictor for various common diseases, serving as a valuable tool for screening and intervention. However, the use of genomic and biomarker data for disease stratification is fraught with complexities and controversies.

These challenges span biological complexity, technical variability, study design limitations, clinical translation hurdles, and operational constraints. For instance, sample heterogeneity and limited availability, particularly in diseases like AML, reduce statistical power and generalizability. Lack of standardization in analytical protocols, variability and inconsistency in biomarker measurement, and small and heterogeneous study populations further complicate matters.

Moreover, the links between some biomarkers and disease phenotypes are poorly understood, and disease and subtype complexity make patient stratification challenging. Translational barriers from discovery to clinical use, operational challenges in clinical trials, and the need for collaborative large-scale studies and harmonization are additional hurdles that need to be addressed.

Emerging technologies such as machine learning and bioinformatics show promise but require independent cohort validation and mechanistic understanding before clinical adoption. The allure of polygenic risk score testing, fueled by commercial interest and the growth in direct-to-consumer genetic testing companies, has contributed to an inflated expectation of their clinical utility.

A polygenic risk score is the sum of independent DNA sequence variants in an individual's genome that influence the risk of a disease. However, a recent BMJ Medicine paper by Aroon Hingorani and his team found poor performance of polygenic risk scores in all applications - population screening, individual risk prediction, and risk stratification.

Aroon Hingorani, a clinician scientist, Consultant in internal medicine and therapeutics at UCL Hospitals, and Professor of Genetic Epidemiology at University College London, focuses on using genetic studies to improve the efficiency of pharmaceutical research and development. He also has an interest in the critical evaluation of genomic and biomarker data for disease prediction.

Risk factors that are causal may be weak predictors, but still worth targeting. For example, lowering blood pressure and cholesterol to prevent heart disease. The controversy surrounding polygenic risk scores could be better resolved by ensuring that their performance is analyzed and presented in ways that have been established over many years for non-genetic screening tests.

The quality of speakers, diversity of topics, and networking opportunities make The Festival of Genomics and Biodata a valuable event for those working in the field. Despite the challenges, the hope that years of genomic research would translate into beneficial clinical impact remains, and the quest for integrated solutions to these challenges continues.

1. Age's significance in predicting various diseases offers a valuable tool for screening and intervention in medical research.
2. The complexities and controversies surrounding genomic and biomarker data usage in disease stratification are considerable.
3. Biological complexity, technical variability, and study design limitations are some of the challenges faced in this area.
4. In diseases like AML, sample heterogeneity and limited availability reduce statistical power and generalizability.
5. Lack of standardization in analytical protocols, variability, and inconsistency in biomarker measurement further complicate matters.
6. Small and heterogeneous study populations add to the intricacies involved in the use of genomic and biomarker data.
7. The links between some biomarkers and disease phenotypes are not well understood, making patient stratification challenging.
8. Disease and subtype complexity exacerbate the difficulties in patient stratification.
9. Translational barriers from discovery to clinical use, operational challenges in clinical trials, and the need for collaborative large-scale studies and harmonization are additional hurdles.
10. Emerging technologies such as machine learning and bioinformatics show promise but need independent cohort validation and mechanistic understanding for clinical adoption.
11. The allure of polygenic risk score testing, driven by commercial interest and the growth in direct-to-consumer genetic testing companies, has inflated expectations of their clinical utility.
12. A polygenic risk score is the sum of independent DNA sequence variants in an individual's genome that influence the risk of a disease.
13. A recent BMJ Medicine paper by Aroon Hingorani and his team found poor performance of polygenic risk scores in all applications.
14. Aroon Hingorani is a clinician scientist, Consultant in internal medicine and therapeutics at UCL Hospitals, and Professor of Genetic Epidemiology at University College London.
15. He has an interest in using genetic studies to improve the efficiency of pharmaceutical research and development.
16. Hingorani also focuses on the critical evaluation of genomic and biomarker data for disease prediction.
17. Risk factors that are causal may be weak predictors, but still worth targeting, such as lowering blood pressure and cholesterol to prevent heart disease.
18. The controversy surrounding polygenic risk scores could be better resolved by analyzing and presenting their performance in ways that have been established for non-genetic screening tests.
19. The quality, diversity of topics, and networking opportunities at The Festival of Genomics and Biodata make it a valuable event for those working in the field.
20. Despite the challenges, the hope that years of genomic research would translate into beneficial clinical impact remains.
21. The quest for integrated solutions to these challenges continues.
22. Biotech, with its advancements in genomics, plays a crucial role in the healthcare industry.
23. Genetic information is increasingly relevant to clinical science, workplace wellness, and mental health, among other medical conditions.
24. Chronic diseases, such as cancer, respiratory conditions, digestive health issues, eye health problems, hearing difficulties, and skin conditions, are influenced by genetics.
25. Fitness and exercise, sexual health, autoimmune disorders, climate change, and mental health are also areas where genetics plays a significant role.
26. Men's health, neurological disorders, and environmental science are interconnected fields that benefit from genomic research.
27. Finance, rich in data and analytics, offers opportunities for investment in genomics-related medical research and biotech.
28. Skin care, therapies, and treatments, nutrition, aging, and women's health are all areas where genomics can provide insights and innovations.
29. Parenting, weight management, and cardiovascular health are also influenced by genetic factors.
30. Industry, Medicare, CBD, and cybersecurity are all fields where genomic research can have an indirect impact.
31. Lifestyle, fashion, food, and investing are areas where genomics can provide personalized recommendations to promote health and wellness.
32. Home and garden, business, personal finance, gadgets, data and cloud computing, technology, artificial intelligence, and relationships are all domains where genomics can influence our daily lives.
33. Pets, travel, cars, books, shopping, social media, movies and TV, entertainment, music, and space and astronomy are fields where understanding genetics can add depth and understanding.

Read also: